Advanced Drug Delivery Systems
GPTKB entity
Properties (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:hasCitations |
Manufacturing Complexity
Regulatory Approval Cost of Development |
| gptkbp:hasCollaboratedWith |
Academic Institutions
Regulatory Agencies Healthcare_Providers |
| gptkbp:hasImpactOn |
Healthcare Costs
Patient_Compliance Therapeutic_Efficacy |
| gptkbp:hasRelatedPatent |
Chronic Disease Management
Cancer Treatment Targeted Therapy |
| gptkbp:hasResearchInterest |
Biomedical Engineering
Nanomedicine Pharmaceutics |
| gptkbp:hasStaff |
Controlled Release
Reduced Side Effects Improved Bioavailability |
| gptkbp:hasTechnology |
Nanotechnology
Liposomes Microspheres Polymeric_Systems |
| https://www.w3.org/2000/01/rdf-schema#label |
Advanced Drug Delivery Systems
|
| gptkbp:isAssociatedWith |
Gene Therapy
Biologics Small Molecules |
| gptkbp:isEvaluatedBy |
Clinical Trials
Preclinical Studies In Vitro Testing |
| gptkbp:isPartOf |
Personalized Medicine
Precision Medicine Regenerative_Medicine |
| gptkbp:isPromotedBy |
Scientific Journals
Industry Publications Medical Conferences |
| gptkbp:isRegulatedBy |
gptkb:FDA
EMA WHO |
| gptkbp:isStudiedIn |
Pharmacology
Toxicology Pharmaceutical_Sciences |
| gptkbp:isUsedIn |
Pharmaceutical Industry
|
| gptkbp:isVisitedBy |
Research Institutions
Universities Pharmaceutical Companies |